Neurocrine Biosciences’ (NBIX) “Buy” Rating Reaffirmed at Canaccord Genuity Group
Canaccord Genuity Group reissued their buy rating on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a report published on Thursday, Benzinga reports. Canaccord Genuity Group currently has a $150.00 price target on the stock. NBIX has been the topic of several other reports. Cantor Fitzgerald reissued an overweight rating on shares of Neurocrine […]
More Stories
Borders & Southern Petroleum (LON:BOR) Trading 9% Higher – Time to Buy?
Shares of Borders & Southern Petroleum plc (LON:BOR – Get Free Report) were up 9% on Wednesday . The company...
Vistry Group (LON:VTY) Stock Price Down 16.1% – Here’s Why
Vistry Group PLC (LON:VTY – Get Free Report) shares fell 16.1% during mid-day trading on Wednesday . The company traded...
Durango Resources (CVE:DGO) Shares Up 25% – Still a Buy?
Durango Resources Inc. (CVE:DGO – Get Free Report)’s share price rose 25% during mid-day trading on Wednesday . The company...
DOGE to Take on Pentagon’s $895.2 Billion Budget
By Jacob Burg Out of all the ambitions of President-elect Donald Trump’s upcoming Department of Government Efficiency (DOGE), one that...
Rio Tinto Group (RIO) – Analysts’ Weekly Ratings Changes
Several brokerages have updated their recommendations and price targets on shares of Rio Tinto Group (LON: RIO) in the last...
Sienna Resources (CVE:SIE) Trading Up 16.7% – What’s Next?
Shares of Sienna Resources Inc. (CVE:SIE – Get Free Report) shot up 16.7% on Wednesday . The stock traded as...